News

Phase 1 trial of bryostatin-1 in MS expected by year’s end

Synaptogenix is teaming up with Cleveland Clinic for a Phase 1 clinical trial involving people with multiple sclerosis (MS) that will test the company’s lead candidate, bryostatin-1 — a therapy designed to prevent cognitive deficits in MS patients. “We are moving forward with our clinical development plans for…

Adhering to treatment is linked to better long-term outcomes

People with multiple sclerosis (MS) who take their prescribed disease-modifying therapies (DMTs) as recommended have better long-term health outcomes and lower healthcare costs than those who don’t, a U.S. study finds. Adhering to treatment can help reduce relapses, slow disease progression, and reduce the economic burden on both…

Can elderly MS patients safely stop treatment? Study aims to find out.

A first-of-its-kind study is aiming to determine whether older adults with multiple sclerosis (MS) can safely stop taking disease-modifying therapies, also known as disease-modifying agents (DMAs). The project is being led by scientists at the new P-HOPER Center, officially the Population Health Outcomes and Pharmacoepidemiology Education and Research…

With Korro Bio merger in works, Frequency stops program for MS

With a planned merger in the works, Frequency Therapeutics is no longer advancing its remyelination therapies for multiple sclerosis (MS), and instead is exploring “strategic alternatives for the program,” the company has announced. The regenerative medicine company, which had aimed to develop a new approach to treating MS…

Use of oral DMTs grew substantially since their launch: US study

Since their launch in the 2010s, the use of oral disease-modifying treatments (DMTs) for multiple sclerosis (MS) has increased substantially, while injectable DMTs have become less popular, according to a study based on U.S. commercial health insurance data. “While two injectable therapies known as platform injectables, were once the…

XPro1595 may promote myelin restoration, new mouse study finds

INmune Bio‘s experimental therapy XPro1595 may promote myelin restoration through the activation of two types of nervous system support cells, according to new data that may lead to novel treatment strategies for multiple sclerosis (MS) and other neurodegenerative disorders. The findings highlight the activation of microglia, key…

Tysabri best of 6 DMTs to prevent relapses, worse disability in MS

Tysabri (natalizumab) is better than five other disease-modifying therapies (DMTs) at reducing relapses and preventing disability worsening in relapsing-remitting multiple sclerosis (RRMS), according to the findings of a novel simulated clinical trial that directly compared the six treatments. The analysis used mathematical modeling to emulate a clinical trial…

Mavenclad found comparable to Gilenya in highly active MS

Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS) patients with highly active disease, according to a new real-world comparison. Disability worsening and the development of new lesions also were similar between the two patient groups — but…

Outcomes better for RRMS patients who start on higher efficacy DMTs

Outcomes are better for people with relapsing-remitting multiple sclerosis (RRMS) initially treated with higher efficacy disease-modifying therapies (DMTs) than for those who begin with lower efficacy DMTs and escalate to more effective treatments as the disease progresses, according to a real-world analysis of patient registry data. Findings also…

CPT code issued for MRI brain scan software by Icometrix

Icometrix‘s quantification software for brain MRI scans has received a Current Procedural Terminology (CPT) III code, a temporary code for emerging technologies that should facilitate reimbursement. CPT codes, issued by the American Medical Association, are designed to identify procedures and services in healthcare plans. They are used in the…

AI algorithms may predict cognitive decline in MS over coming year

Researchers have developed computer algorithms that may be able to predict certain aspects of cognitive change in multiple sclerosis (MS) patients. The prediction models, constructed using data from an electronic, self-administered test of information processing speed given MS patients, might accurately identify those likely to experience cognitive worsening over…

Aubagio shifts immune cell balance in RRMS, study reveals

Aubagio (teriflunomide), an approved therapy for relapsing forms of multiple sclerosis (MS), works by shifting the balance between activated subsets of nerve-damaging immune cells to those with immunosuppressive traits, a new study reveals. Further studies to understand how changes in immune cell subsets drive Aubagio’s clinical effectiveness will…

Newly discovered genetic variant tied to faster MS progression

Researchers identified a genetic variant that associated with faster multiple sclerosis (MS) progression and greater brain tissue damage, according to a study that combined data on more than 12,500 patients in North America, Europe and Australia. Unlike previously detected MS-related variants linked to the immune system, this variant sits…